[1]Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al.: 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022, 43:3997-4126.[2]Funder JW, Carey RM, Mantero F, et al.: The management of primary aldosteronism: case detection,diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016,101:1889-916.[3]Turcu AF, Yang J, Vaidya A: Primary aldosteronism - a multidimensional syndrome . Nat Rev Endocrinol.2022, 18:665-82.[4]Käyser SC, Dekkers T, Groenewoud HJ, et al.: Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab. 2016, 101:2826-35.[5]Diercks DB, Shumaik GM, Harrigan RA, Brady WJ, Chan TC Electrocardiographic manifestations: electrolyte abnormalities. J Emerg Med. 2004, 27:153-60.[6]Kardalas E, Paschou SA, Anagnostis P, Muscogiuri G, Siasos G, Vryonidou A: Hypokalemia: a clinical update .Endocr Connect. 2018, 7:R135-46.[7]Burrello J, Monticone S, Losano I, et al.: Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit. Hypertension. 2020, 75:1025-33.[8]Rossi GP, Cesari M, Cuspidi C, et al.: Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013, 62:62-9.